A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis (2MD-7H-2B)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01922843
Recruitment Status : Completed
First Posted : August 14, 2013
Last Update Posted : August 18, 2017
Information provided by (Responsible Party):
Deltanoid Pharmaceuticals

Brief Summary:
The goal of this study is to test a new vitamin D compound for its ability to reduce parathyroid hormone levels in patients who are on hemodialysis.

Condition or disease Intervention/treatment Phase
Hyperparathyroidism, Secondary Kidney Failure, Chronic Drug: DP001 softgel capsules Drug: Placebo Phase 2

Detailed Description:
This is a randomized, double-blind, placebo-controlled study of the vitamin D analog 2-methylene-19-nor-20S-1α,25-dihydroxyvitamin D3 (DP001) in patients with end-stage renal disease (ESRD). The effect of 12 weeks of oral administration of DP001 on serum parathyroid hormone (PTH) levels will be evaluated in ESRD patients who have secondary hyperparathyroidism.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
Study Start Date : September 2013
Actual Primary Completion Date : May 2014
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis Vitamin D
Drug Information available for: Vitamin D

Arm Intervention/treatment
Experimental: DP001
DP001 softgel capsules, 440 ng taken orally three times weekly after dialysis for 12 weeks
Drug: DP001 softgel capsules
Other Names:
  • 2-methylene-19-nor-20S-1α,25-(OH)2D3
  • PF-00217763
  • 2MD

Placebo Comparator: Placebo
Placebo softgel capsules, taken orally three times weekly after dialysis for 12 weeks
Drug: Placebo
Other Name: Placebo soft gel capsules

Primary Outcome Measures :
  1. The proportion of patients who achieve two consecutive > or = 30% decreases from his/her baseline serum iPTH level [ Time Frame: 12 weeks, with weekly iPTH measurements ]

Secondary Outcome Measures :
  1. Mean percentage change in serum iPTH [ Time Frame: Baseline to 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and non-pregnant women ≥18 years of age
  • Patient is diagnosed with ESRD and must be on hemodialysis 3 times per week for at least 3 months prior to Screening Phase
  • Patient is currently being treated with pharmaceutical vitamin D for the treatment of secondary hyperparathyroidism
  • Serum iPTH value ≤500 pg/mL at first screening visit
  • Total serum calcium (corrected for albumin) ≤10.5 mg/dL at first screening visit
  • Serum phosphorus ≤7.0 mg/dL at first screening visit

Exclusion Criteria:

  • Currently taking any of the following: drugs affecting vitamin D metabolism, digitalis, glucocorticoids, cyclosporine or other immunosuppressants, aluminum-based phosphate binders
  • A daily intake >4000 IU vitamin D (D3 + D2)
  • Any investigational drug use within 10 half-lives of the drug (or within the previous 30 days if the half-life of the drug is unknown)
  • History of any of the following: ventricular dysrhythmias, severe congestive heart failure, angina pectoris, myocardial infarction, coronary angioplasty, coronary artery bypass grafting, multiple myeloma, calciphylaxis, active malignancy, end-stage liver disease, active infections, clinically significant renal/urinary tract stones, sarcoidosis, tuberculosis, parathyroidectomy
  • Major surgery within the past 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01922843

United States, Arizona
Phoenix, Arizona, United States
Tucson, Arizona, United States
United States, District of Columbia
Washington, D.C., District of Columbia, United States
United States, Illinois
Evanston, Illinois, United States
United States, Missouri
Saint Louis, Missouri, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New York
Great Neck, New York, United States
Ridgewood, New York, United States
United States, North Carolina
Charlotte, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
United States, Tennessee
Nashville, Tennessee, United States
United States, Texas
Fort Worth, Texas, United States
Grand Prairie, Texas, United States
San Antonio, Texas, United States
Sponsors and Collaborators
Deltanoid Pharmaceuticals
Study Chair: Ravi Thadhani, MD Massachusetts General Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Deltanoid Pharmaceuticals Identifier: NCT01922843     History of Changes
Other Study ID Numbers: 2MD-7H-2B
First Posted: August 14, 2013    Key Record Dates
Last Update Posted: August 18, 2017
Last Verified: August 2017

Keywords provided by Deltanoid Pharmaceuticals:

Additional relevant MeSH terms:
Neoplasm Metastasis
Renal Insufficiency
Hyperparathyroidism, Secondary
Kidney Failure, Chronic
Neoplastic Processes
Pathologic Processes
Kidney Diseases
Urologic Diseases
Parathyroid Diseases
Endocrine System Diseases
Renal Insufficiency, Chronic
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents